May 10, 2021

Huntsman Cancer Institute Congratulates Faculty on Recent Academic Honors

Huntsman Cancer Institute recognizes new and renewed endowed chairs, along with the distinguished professorship of faculty. Endowed chairs play an important role in creating a partnership between donors and researchers. Distinguished professors are recognized for academic achievements and dedication to teaching.

Mar 29, 2021

Huntsman Cancer Institute Appoints Neeraj Agarwal, MD, as Senior Director of Clinical Research Innovation

Huntsman Cancer Institute announced the appointment of physician-scientist Neeraj Agarwal, MD, as senior director of clinical research innovation. Agarwal will serve on the senior leadership of the Comprehensive Cancer Center at HCI, oversee critical components of HCI’s clinical research infrastructure, and will lead efforts to accelerate the process of bringing new, innovative clinical trial offerings to patients.

Jan 28, 2021

Huntsman Cancer Institute Joins Leading Cancer Organizations to Warn Cancer Doesn’t Stop for COVID-19 and Neither Should You

Huntsman Cancer Institute is teaming up with the National Comprehensive Cancer Network®, the American Cancer Society, and other leading organizations across the country to endorse resuming cancer screening and treatment during the ongoing COVID-19 pandemic. The coalition released a letter stating that cancer still poses a major threat to people’s health.

Jan 20, 2021

American Society of Hematology Selects Ami Patel to Receive a 2021 ASH Scholar Award

HCI physician-scientist Ami Patel, MD, has been selected by the American Society of Hematology (ASH) to receive a Scholar Award for her research in leukemia. ASH Scholar Awards are one of ASH’s most prestigious research award programs. They provide financial support to fellows and junior faculty who have dedicated their careers to advancing the field of hematology research as they transition from training programs to careers as independent investigators.

Dec 07, 2020

Huntsman Cancer Institute Treats First Non-Small Cell Lung Cancer Patient on New Phase I Clinical Trial

The first patient in the world to be enrolled on a clinical trial of a new investigational drug, AN0025, was treated at Huntsman Cancer Institute at the University of Utah earlier this year. The drug is being studied for use in patients with non-small cell lung cancer and other solid tumors who have previously been treated with immunotherapy and whose cancers later developed ways to resist immunotherapy.

Dec 03, 2020

Huntsman Cancer Institute Researchers Identify Promising Drug Combination for Melanoma

Researchers at Huntsman Cancer Institute at the University of Utah have identified a potential drug combination to treat uveal melanoma, a type of eye cancer. Lead author Amanda Truong, trainee in the McMahon Lab at HCI, explains uveal melanoma patients frequently have changes in genes called GNAQ and GNA11, which are key targets for these drugs. This study was published in the journal Clinical Cancer Research.

Nov 27, 2020

Fighting Melanoma and Other Cancers Using Immunotherapy

For Siwen Hu-Lieskovan, MD, PhD, it was the promise of immunotherapy—that is, harnessing the body’s own immune system to fight cancer—that inspired her to get into cancer research. Training under one of the pioneers of immunotherapy, she witnessed amazing survival stories of patients. The project Hu-Lieskovan proposed for the 5 For The Fight grant is to tackle the immune-related adverse events when adding different immunotherapies.

Nov 12, 2020

Huntsman Cancer Institute Researcher Receives National Cancer Clinical Investigator Team Leadership Award

Siwen Hu-Lieskovan, PhD, MD, physician scientist at Huntsman Cancer Institute and assistant professor of medicine at the University of Utah, has received the National Cancer Institute 2020 Cancer Clinical Investigator Team Leadership Award. The award recognizes outstanding clinical investigators at NCI-designated Cancer Centers who participate extensively in NCI-funded clinical trials, and whose leadership and activities promote a successful culture of collaborative clinical research.